You have full access to this article via your institution. These results demonstrate a potential therapeutic option for the manipulation of regulatory T cells for the purpose of activating effector ...
Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: A comparative study with histology, proangiogenic cytokines and clinical markers This is an ASCO Meeting Abstract ...
A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies. This is an ASCO Meeting Abstract from the 2021 ASCO Annual ...
Protein power A protein that could be harnessed to prevent or reverse the onset of type 1 diabetes has been identified by Australian researchers. The researchers found the protein - CD52 - plays a key ...
BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company leading the field of epitope shielding, is presenting data for its CD52 program during this week’s ...
Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...
Researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results